Papaxoinis, George http://orcid.org/0000-0001-6900-784X
Kotoula, Vassiliki
Giannoulatou, Eleni
Koliou, Georgia-Angeliki
Karavasilis, Vasilios
Lakis, Sotirios
Koureas, Andreas
Bobos, Mattheos
Chalaralambous, Elpida
Daskalaki, Emily
Chatzopoulos, Kyriakos
Tsironis, George
Pazarli, Elisavet
Chrisafi, Sofia
Samantas, Epaminontas
Kaklamanos, Ioannis G.
Varthalitis, Ioannis
Konstantara, Athina
Syrigos, Konstantinos N.
Pentheroudakis, George
Pectasides, Dimitrios
Fountzilas, George
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping
https://doi.org/10.1007/s12032-018-1160-1
Funding for this research was provided by:
Amgen Ltd
Hellenic Cooperative Oncology Group
Article History
Received: 14 May 2018
Accepted: 27 May 2018
First Online: 31 May 2018
Compliance with ethical standards
:
: VKar: Advisory Board of Amgen, Pfizer, Novartis, BI, Lilly, Astellas, Genesis-Pharma, and Janssen. SL: Employee of NEO New Oncology GmbH and Consultant BioTech AG. ES: Advisory Board of Merck, MSD, Astra-Zeneca, Roche, Amgen, and Genesis. GF: Advisory Board of Pfizer, Sanofi, and Roche. Honoraria from Astra-Zeneca. The rest of the authors declare that they have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The clinical protocol was approved by the Institutional Review Boards of Papageorgiou General Hospital, Ioannina University Hospital, Agii Anargiri Cancer Hospital, Sotiria General Hospital, Alexandra Hospital, Patra University Hospital, Metropolitan Hospital, Hygeia Hospital, Chania General Hospital, Hippokration Hospital, and by the National Organization for Medicines. The trial was registered with the ClinicalTrials.gov identifier: NCT01215539. The translational research protocol was approved by the Institutional Review Board of the Papageorgiou General Hospital (08/04/2009 #233).
: Informed consent was obtained from all individual participants included in the study. In addition, patients who were willing to provide biological material for future translational research studies signed a separate informed consent.